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a b s t r a c t
Background and objective: In Latvia, like in other European countries, the incidence of diabetes
mellitus is increasing and so it is important to find out what the trends in the mortality of
diabetes mellitus in Latvia are. The aim of this study was to calculate the mortality indicators
of diabetes patients in Latvia from 2000 to 2012 and compare mortality among diabetes
mellitus patients with mortality among the population of Latvia.
Materials and methods: The study was carried out with a quantitative statistical analysis
approach. In the study, all the registered patients with diabetes mellitus from 2000 to 2012
were included.
Results: Mortality in a population with diabetes decreased statistically significantly from
57.76 per 1000 py in 2000 to 45.33 per 1000 py in 2012. In the general population of Latvia,
there were no statistically significant changes; the mortality in 2000 was 13.56 per 1000 py, in
2012 – 14.24 per 1000 py. The age-standardised mortality ratio of the population with
diabetes and the population of Latvia decreased from 1.71 (95% CI = 1.62–1.81) in 2000 to
1.23 (95% CI = 1.19–1.27) in 2012.
Conclusions: In Latvia the mortality of patients with diabetes exceeds mortality in the general
population. Mortality rates are higher for men and older patients, however, compared to
mortality in the general population, diabetes increases the risk of death; especially for
women and for younger patients. There is a tendency that the mortality indicators of
patients with diabetes and mortality indicators in the general population are becoming
closer.
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The International Diabetes Federation has estimated that 35
million adults had diabetes mellitus in Europe in 2011 and it is
likely that there will be 43 million (increase will be 23%) in 2030.
The estimated prevalence of diabetes mellitus differs and
varies among the countries from 2.8% in Albania to 9.8% in
Portugal [1]. The prevalence of diabetes mellitus was 3.8% in
Latvia at the end of 2012 (79 122 patients with diabetes
mellitus) [2]. With the increasing incidence of diabetes
mellitus, the mortality of these patients is becoming a more
and more important problem. Diabetes mellitus is in fourth
and fifth place in the structure of causes of death in Europe.
The studies show that diabetes mellitus patients have a higher
risk of death than people without diabetes mellitus [3–13].
Most patients with diabetes mellitus die from disease related
complications – about 50% of patients with diabetes mellitus
die of cardiovascular diseases, 10–20% of renal insufficiency
[14]. The aim of high quality diabetes care is to remove or
prevent the complications of diabetes, thereby reducing the
diabetes-related premature death risk. Consequently, the
diabetic patient mortality or survival indicators can serve as
diabetes care quality criteria [15].
In developed countries, the overall age-standardised
mortality in the population is decreasing, while age-standar-
dised mortality among diabetes mellitus patients is increasing
[16,8,17]. Geiss et al. [17] found out that the age-standardised
mortality of persons with diabetes mellitus is two times higher
than the age-standardised mortality of non-diabetic persons.
Several previous studies have shown higher relative mortality
rates observed in younger age groups of type 2 diabetes
mellitus patients; it suggests the relative importance of this
cause compared to other causes, particularly in younger age
groups. Older people, whose total mortality risk is higher, have
a lower diabetes-specific death risk [13].
However, research has not shown consistency, because it
has been observed in several studies that the mortality
indicators are decreasing [12,13,18] not only in the general
population but also among diabetes mellitus patients, which
could be a sign of diabetes care improvement. However,
mortality is also decreasing in the general population in many
countries. Therefore, it is not self-evident that the decrease of
mortality indicators among people with diabetes is conse-
quences of better care. If preferred it can only reflect trends in
the general population. Therefore, studies often use the term
‘‘relative mortality’’ or ‘‘relative mortality rate,’’ which
indicates how many times the mortality among patients with
diabetes mellitus exceeds mortality in the general population
[4,6,7,10,11,13] or mortality among people who do not have
diabetes [3,5,8,9,12].
In Latvia, like in other European countries, the incidence of
diabetes mellitus is increasing and it is important to find out
what the trends in mortality of diabetes mellitus in Latvia are
and to compare them with trends in mortality in the general
population.
The aim of this study was to calculate the mortality
indicators of diabetes mellitus patients in Latvia from 2000 to
2012 and compare mortality among diabetes mellitus patients
with mortality among the population of Latvia.2. Materials and methods
The study was carried out with a quantitative statistical
analysis approach. Included in the study, were all the patients
with diabetes mellitus, who from 2000 to 2012, have been in
the records of the ‘‘Register of patients with particular
diseases, including patients with diabetes mellitus’’ (herein-
after – The Register of diabetes). In Latvia the Register of
diabetes was launched in 1997 by Latvian Association of
Endocrinologists. Since 2004 it has been under the supervision
of institutions subordinate to the Ministry of Health. Currently
the Register of diabetes is a part of the united Register of
patients with particular diseases. The Centre for Disease
Prevention and Control is the register administrator and
holder. The register activity is stipulated by the regulations of
The Cabinet of Ministers of the Republic of Latvia which
requires that family doctors and endocrinologists give
information to the register at least once a year by filling in a
special form about each patient with diabetes mellitus that
they take care of. The number of registered patients with
diabetes mellitus is growing and hence the completeness of
the register is also growing every year, so data from the first
four years of the register were not included. Since 2009 the
information in the Register of diabetes has been compared to
the reimbursed medicine database maintained by The
National Health Service. As a result of the comparison lists
of patients who receive reimbursed medicine for diabetes are
obtained, but there is a lack of information about them in the
Register of diabetes. Information is entered in the Register of
diabetes in collaboration with physicians, so the register staff
estimate that the register coverage is 90% of all patients with
diabetes mellitus who receive state reimbursed medicine. Data
from the Death causes database of the Centre for Disease
Prevention and Control about the number of persons who died
from 2000 to 2012 were also used, as well as Central Statistical
Bureau data about the average number of the population of
Latvia in 2000–2012 by gender and age groups.
Mortality was calculated as a rate per 1000 person-years
(py). Death cases of patients with diabetes mellitus that were
in the record of the register were considered a case, regardless
of the cause of death. In total from 2000 to 2012 there were
34 072 death cases (12 351 for men and 21 721 for women) and
the population included in the study was 691 042 person-years
(229 447 for men and 461 575 for women) [2].
To calculate the mortality indicators of the general
population of Latvia data were used from the Death causes
database of the Centre for Disease Prevention and Control
about the number of persons who died from 2000 to 2012 and
officially published data on the website of the Central
Statistical Bureau about the average number of the population
of Latvia corresponding to the certain period of time which are
recalculated according to Population Census 2011 [19]. By
dividing the mortality among patients with diabetes by the
mortality in the general population, the so-called relative
mortality rate was obtained. All parameters were calculated
separately for men and women. In addition, since the age
structure of patients with diabetes and the population of
Latvia differ significantly, diabetes patients are older (more
than 90% of those registered are type 2 diabetic patients [2]),
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Furthermore, the age-standardised mortality ratio (SMR) was
calculated using the indirect standardisation method [20]. The
mortality of the Latvian population and the population of
people with diabetes in 20–79 year old group with a 10-year
interval were used.
In the case of the mortality rate and the standardised
mortality ratio 95% confidence intervals (CI) were calculated,
but in the case of the relative mortality rate – the method of
comparison of two parameters of incidence rate – rate ratio
[21]. The difference was statistically significant, when 95% CI of
relevant indicators did not overlap or 95% CI did not included 1
as it is in the case of the relative mortality rate and the
standardised mortality ratio.
The changes of parameters from 2000 to 2012 were
analysed with the linear regression method. Mean changes
in indicators during the year were characterised by the
regression coefficient b and statistical significance – P value.
3. Results
In total during 2000–2012 the mortality rate of men in the
Register of patients with diabetes was 56.41 per 1000 py (95%
CI = 55.41–57.41) and among women 49.03 per 1000 py (95%
CI = 48.38–49.69). The total 13-year mortality rate of the
diabetic population was 51.47 per 1000 py (95% CI = 50.93–
52.02). In the same period of time, mortality rate among the
Latvian population was 15.35 per 1000 py (95% CI = 15.28–15.41)
for men and 13.27 per 1000 py (95% CI = 13.22–13.33) for
women; the overall mortality rate over a 13-year period was
14.23 per 1000 py (95% CI = 14.18–14.27).
Analysing the changes of mortality over a 13-year period,
Fig. 1 shows that mortality rate in the population with diabetes
decreased statistically significantly from 57.76 per 1000 py (95%
CI = 54.71–60.94) in 2000 to 45.33 per 1000 py (95% CI = 43.85–
46.86) in 2012. According to the regression equation in Fig. 1, it is
clear that each year the mortality rate in the population with
diabetes decreased by 1.16 cases per 1000 py (b = 1.16; P < 0.001)
on average. In turn, in the general population of Latvia, there
were no statistically significant changes; the mortality rate in
2000 was 13.56 per 1000 py (95% CI = 13.41–13.71), in 2012 was
14.24 per 1000 py (95% CI = 14.08–14.41) (b = 0.02; P = 0.478).30.068y = 0.0221x -
R² = 0.0461; p>0.0 5
y = -1.










Fig. 1 – Mortality rate in a population with diabetes and Analysing mortality by gender, Fig. 2 shows that both
female and male mortality rate in the population with diabetes
declined. Male mortality rate in the population with diabetes
has decreased from 64.37 (95% CI = 58.67–70.47) in 2000 to 54.74
per 1000 py (95% CI = 51.17–58.50) in 2012. Every year the
mortality rate of the diabetic male population has reduced by
1.57 cases per 1000 py (b = 1.57; P < 0.001). A mortality
reduction in the diabetic female population was observed,
but it is less than in the male population; over a 13 year period,
mortality rate in the female population has decreased by 1 case
per 1000 py every year (b = 1.00; P < 0.001). In the general
population of Latvia men have had an insignificant decline in
mortality which was not statistically significant (b = 0.03;
P = 0.542) and over a 13 year period a small increase in the
mortality of the general population of Latvia women – every
year the increase in mortality rate was 0.06 cases per 1000 py
(b = 0.06; P = 0.024).
Analysing the total relative mortality rate of diabetic
patients compared to the general population of Latvia, Table 1
shows that it has decreased from 4.08 (95% CI = 3.87–4.30) in
2000 to 3.09 (95% CI = 2.98–3.19) in 2012. The relative mortality
rate in the diabetic male population compared to the general
population of Latvia has decreased from 4.14 (95% CI = 3.79–
4.53) in 2000 to 3.14 (95% CI = 2.97–3.32) in 2012. The female
diabetic population has also experienced a slight decrease in
relative mortality rate compared to the general population of
Latvia; the decrease in relative mortality rate went from 4.2
(95% CI = 3.93–4.49) in 2000 to 3.09 (95% CI = 2.96–3.23) in 2012.
Comparing diabetic patient mortality between men and
women by age group (Table 2), in all age groups after the
age of 29, the mortality rate of men was statistically
significantly higher than the mortality rate of women (the
lowest 95% confidence limit of mortality rate estimate in
women was higher than the upper 95% confidence limit of
estimate in men). While in the age group below 20, these
differences were not statistically significant. It is not unex-
pected that mortality rate increases with the increase of a
patients' age.
The comparison of mortality rate indicators of diabetic
patients with the mortality of the general population of Latvia
showed that women with diabetes had higher relative
mortality rate than men (Table 3). For example, in the 20- to
29-year-old women group with diabetes, the mortality rate1622x + 2384.4
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Fig. 2 – Mortality rate differences by gender in a population with diabetes and general population of Latvia 2000–2012, per
1000 py.
m e d i c i n a 5 0 ( 2 0 1 4 ) 1 3 0 – 1 3 6 133was 11 times higher than that of women in the population of
Latvia in the same age group, but in the 30–39 age group –
nearly seven times bigger. The mortality rate of men with
diabetes compared to that of men in the population of Latvia
was increased most in the 20–29 age group – by more than 4
times.
The mortality rates of men and women with diabetes, by
increasing age group, came closer the mortality in the general
population of Latvia in corresponding age groups, up to 80
years and over the mortality rate indicators of diabetic patients
and the population of Latvia were similar.
Analysing the age-standardised mortality ratio of the
population with diabetes and the population of Latvia, Table 4
shows that it has decreased from 1.71 (95% CI = 1.62–1.81) in
2000 to 1.23 (95% CI = 1.19–1.27) in 2012. The standardised
mortality ratio of diabetic men compared to the population of
Latvian men has decreased from 1.60 (95% CI = 1.46–1.74) in
2000 to 1.22 (95% CI = 1.15–1.29) in 2012. The standardised
mortality ratio of the female population has decreased from
1.78 (95% CI = 1.66–1.90) in 2000 to 1.29 (95% CI = 1.23–1.34) in
2012. This means that mortality among diabetic patientsTable 1 – Relative mortality rate (95% CI) of patients with
diabetes who are in the Register of diabetes in compar-
ison to the general population of Latvia 2000–2012.
Year Total Male Female
RR 95% CI RR 95% CI RR 95% CI
2000 4.08 3.87–4.30 4.14 3.79–4.53 4.20 3.93–4.49
2001 3.99 3.80–4.19 4.10 3.85–4.52 4.00 3.80–4.30
2002 3.89 3.71–4.07 4.02 3.73–4.34 3.93 3.71–4.16
2003 3.85 3.69–4.02 3.98 3.70–4.28 3.89 3.68–4.10
2004 3.85 3.69–4.01 3.88 3.63–4.16 3.96 3.76–4.16
2005 3.69 3.55–3.84 3.71 3.48–3.96 3.83 3.65–4.03
2006 3.47 3.34–3.61 3.49 3.28–3.72 3.59 3.43–3.77
2007 3.45 3.32–3.58 3.63 3.43–3.85 3.44 3.28–3.61
2008 3.46 3.34–3.59 3.51 3.32–3.73 3.53 3.37–3.69
2009 3.31 3.19–3.43 3.36 3.17–3.57 3.34 3.19–3.50
2010 3.18 3.07–3.29 3.15 2.97–3.34 3.27 3.13–3.42
2011 3.31 3.19–3.42 3.78 3.58–3.98 3.33 3.19–3.48
2012 3.09 2.98–3.19 3.14 2.97–3.32 3.09 2.96–3.23tended to move closer to mortality in the general population. It
was however still 1.22 times higher for men with diabetes and
for women 1.29 times higher in comparison to the correspond-
ing gender of the population of Latvia.
Analysing the linear regression coefficient for the standar-
dised mortality ratio by gender, Fig. 3 shows that both the total
SMR, and the decrease by gender separately, was linear; it is a bit
steeper for women than men. The SMR for women decreased by
0.037 (b = 0.04; P < 0.001), but for men by 0.032 (b = 0.03;
P < 0.001) every year.
4. Discussion
In this study, based on the data of the Register of diabetes, the
mortality of diabetic patients in Latvia in the period of 2000–2012
was calculated, and mortality changes over a 13-year period
were also evaluated. The overall mortality rate in the population
with diabetes was 56.41 per 1000 py for men and 49.03 per
1000 py for women, which was almost four times more than
among the population of Latvia. The total 13-year mortality rate
in the population with diabetes was 51.47 per 1000 py, while in
the general population of Latvia it was 14.18 per 1000 py. During
this period the diabetic population had a mortality rate 3.6 times
higher than in the general population of Latvia.Table 2 – The mortality rate of patients with diabetes who
are in the Register of diabetes per 1000 py (95% CI) by age
group in Latvia 2000–2012.
Age group Male Female
Mortality 95% CI Mortality 95% CI
<20 1.82 0.73–3.76 1.17 0.32–2.99
20–29 9.70 7.02–13.07 4.96 3.07–7.57
30–39 18.64 15.94–21.66 8.68 6.57–11.24
40–49 23.00 21.14–24.97 10.42 9.12–11.86
50–59 31.93 30.38–33.53 15.40 14.51–16.32
60–69 52.29 50.55–54.07 29.15 28.26–30.06
70–79 94.06 91.35–96.84 63.01 61.72–64.32
80+ 164.54 157.5–171.82 144.01 140.72–147.35
Table 3 – The relative mortality rate of diabetic patients who are in the Register of diabetes in comparison to general
population of Latvia by age groups.
Age group Total Male Female
RR 95% CI RR 95% CI RR 95% CI
<20 2.42 1.34–4.38 2.37 1.13–4.97 2.47 0.93–6.59
20–29 5.98 4.68–7.65 4.47 3.31–6.02 11.34 7.34–17.45
30–39 5.19 5.56–5.92 4.33 3.37–5.03 6.67 5.21–8.78
40–49 2.83 2.64–3.04 2.47 2.23–2.69 3.42 2.99–3.89
50–59 1.75 1.69–1.82 1.62 1.54–1.70 2.25 2.12–2.39
60–69 1.50 1.47–1.54 1.34 1.29–1.38 1.99 1.93–2.06
70–79 1.44 1.42–1.47 1.30 1.27–1.34 1.65 1.62–1.69
80+ 1.09 1.07–1.12 1.04 0.99–1.08 1.12 1.09–1.15
m e d i c i n a 5 0 ( 2 0 1 4 ) 1 3 0 – 1 3 6134In developed countries, the age-standardised mortality
ratio in the general population is decreasing while the
standardised mortality ratio in the diabetes population is
increasing [16,8,17]. In Latvia there was a tendency that
mortality rate in the general population was almost un-
changed, but mortality rate in the population with diabetes
decreased and became level to mortality in the general
population.
Geiss et al. [17] found out that the age-standardised death
rate of persons with diabetes is two times higher than for those
without diabetes. There were not such big differences in the
age-standardised mortality observed in Latvia. The difference,
measured by the SMR, decreased from 1.71 in 2000 to 1.23 in
Latvia in 2012. During the entire observation period, women
had higher age-standardised mortality ratios than men, but
they also had a tendency to decrease. In the research, more
attention is paid to the comparison of age-specific mortality
rates, because the age structures of the population of diabetic
patients and the general population or the population without
diabetes are very different. It is natural that the older the
diabetic patients are, the more mortality increases. In Latvia
the mortality rate of patients who were younger than 20, was
1.82 per 1000 py for men and 1.17 per 1000 py for women, but
for patients who were 80 and older – 164.54 per 1000 py for men
and 144.01 per 1000 py for women.
A direct comparison of Latvia indicators with other studies
limits the differences in research methods to some extent:
selected age groups, patient characteristics (all patients or ay = -0.0326x + 1.636 8
R² = 0.9288;  p<0.001
y = -0.












Fig. 3 – The standardised mortality ratio (95% CI) in the period 2
diabetic patients who are in the Register of diabetes to the mortparticular type of diabetes, all existing patients or only newly
diagnosed patients and the duration of the study).
Several previous studies have shown that higher relative
mortality rates are observed in younger age groups of type 2
diabetes patients, suggesting the relative importance of this
cause compared to other causes particularly in younger age
groups. The diabetes-specific risk of death is less for older
persons with a higher total mortality risk [13]. In Latvia the
highest relative mortality rate was in the 20- to 29-year-old
group and 30- to 39-year-old group; the mortality of these
groups in the population with diabetes was more than five
times higher than in the general population; the difference
was not so great in other age groups, and there was no
difference in the mortality of the population with diabetes and
the general population in the age group above 80. Such a
relationship, that the relative mortality rate of diabetic
patients is highest in the younger age groups and decreases
with age, is confirmed in a large number of studies [3–6,8–
10,13]. In the research carried out in other countries, mortality
in younger age groups is significantly lower than in Latvia; for
example, in the research carried out in the UK, mortality in the
age group up to 39 years old was 2.59 per 1000 py for men and
2.43 per 1000 py for women [3].
The numerical values of relative mortality rate depend on
the research methods used, as well as on whether the general
population has been taken as a reference group (which also
includes diabetic patients), or just persons without diabetes.
But in any case, in creating this indicator, it is taken intoy = -0.0377x + 1.767 1
R² = 0.9317; p<0.00 1








000–2012: linear regression of comparison of mortality of
ality of the population of Latvia.
Table 4 – Standardised mortality ratio (95% CI) in the
period 2000–2012. The mortality of diabetic patients who
are in the Register of diabetes in comparison to the
mortality of general population of Latvia.
Year Male Female Total
SMR 95% CI SMR 95% CI SMR 95% CI
2000 1.60 1.46–1.75 1.78 1.66–1.90 1.71 1.62–1.81
2001 1.61 1.48–1.75 1.69 1.59–1.80 1.66 1.58–1.75
2002 1.55 1.44–1.68 1.63 1.54–1.73 1.53 1.46–1.60
2003 1.51 1.40–1.63 1.59 1.51–1.67 1.49 1.43–1.56
2004 1.47 1.37–1.58 1.62 1.54–1.70 1.50 1.39–1.56
2005 1.42 1.33–1.52 1.57 1.49–1.65 1.45 1.39–1.51
2006 1.35 1.26–1.43 1.47 1.41–1.54 1.37 1.32–1.42
2007 1.41 1.33–1.49 1.39 1.33–1.46 1.35 1.31–1.41
2008 1.33 1.26–1.41 1.41 1.35–1.48 1.34 1.29–1.38
2009 1.28 1.20–1.35 1.36 1.30–1.42 1.29 1.24–1.34
2010 1.24 1.17–1.31 1.36 1.30–1.42 1.28 1.23–1.32
2011 1.32 1.25–1.39 1.38 1.33–1.44 1.32 1.28–1.37
2012 1.22 1.15–1.29 1.29 1.23–1.34 1.23 1.19–1.27
m e d i c i n a 5 0 ( 2 0 1 4 ) 1 3 0 – 1 3 6 135account what the mortality rate of the general population or in
the non-diabetic population in the relevant age groups is. Thus
it can be concluded that diabetes increases the premature
death risk for younger people more significantly.
Research comparing the differences of diabetic patient
mortality among genders, quite clearly shows that the
mortality indicators of men are higher [3,9,13,22]. In Latvia
the mortality of diabetic patients in all age groups was higher
for men than women, and these differences were only not
statistically significant up to the age of 29.
However, the gender relation to an increased risk of death
looks different when comparing the relative mortality indi-
cators and the mortality level for men and women in the
general population or in the population without diabetes is
taken into account.
In Latvia the relative mortality rate of women with diabetes
compared to women in the general population was higher
than that among men in almost all age groups, except the age
group younger than 20, and the standardised mortality ratio
also was higher among women than among men, for example,
it was 1.29 vs. 1.22 in 2012.
An interesting question arises about the reasons for
mortality changes of patients with diabetes during the period
of time. Early diagnosis of diabetes, the tight/intensified
control of glycemia, hypertension, dyslipidemia and other
risk factors, as recommended by the diabetes treatment and
care guidelines of Latvia [23–25], could not only reduce the
incidence of diabetic complications but also mortality. In this
research, all diabetic patient deaths, regardless of whether
diabetes was or was not recorded in the causes of death
certificates, were included in the calculation of diabetic patient
mortality. The results show that over a 13-year period the
mortality of diabetic patients in Latvia has slightly decreased,
and in 2012 the mortality rates for both men and women were
lower than in previous years. This 13-year period had a
tendency to level out the differences between mortality among
patients with diabetes and mortality in the general population
of Latvia, for both men and women.
The study has the advantage of using the Register of
diabetes, because a selection based on the entire populationis much more representative than a selection made, for
example, from a hospital or clinical trial patients. In theory,
this register should include all patients diagnosed with diabetes
in Latvia; it is questionable whether the registry is so
comprehensive, the register staff estimate that the register
coverage is 90% of all patients with diabetes mellitus who
receive state reimbursed medicine. It is difficult to say whether
and how potential registry failures may affect the results of the
given research. If we assume that the register is relatively less
represented with patients with a mild form of diabetes (for
example, using only diet as a treatment) and wealthier persons
using private services, then in this research, calculated
mortality indicators could be higher than in reality. But it could
also be vice versa. If the primary care physicians who are less
interested in diabetes treatment and provide a lower quality of
care, have not given information about their diabetic patients to
the register, then according to the register data the calculated
mortality indicators are better.
In this study, the mortality of patients with diabetes was
compared to mortality in the general population, which
includes people with diabetes, not only people without diabetes.
Thus calculated, the diabetes-related premature death risk is a
bit lower. It depends on the extent to which the prevalence of
diabetes in the general population by age group reduces the
numerical value of the relative risk. However, this approach – to
compare with the general population – is widely used
[4,6,7,10,11,13], because demographic statistics on population
and deaths in age groups in the countries are available.
Moreover, even if the reference group – people without diabetes
– is established (for example, by subtracting the number of
diabetics patients in each age group from the number of the
population, or on the basis of the health authorities' databases),
it can still include currently unknown type 2 diabetes mellitus
patients in the latent phase of disease.
To make the results of the research applicable in clinical
practice, aspects such as the type of diabetes, duration of
diabetes, causes of death, and even factors such as lifestyle
habits should be included in the analysis. For example, studies
have shown that cardiovascular diseases are the leading cause
of an increased death risk of patients with diabetes [3,5,7,9–12].
However, the relatively small population of Latvia and hence the
small number of people with diabetes, makes it difficult to create
indicators for smaller sub-groups. Right now a small number of
cases in younger age groups prevent the interpretation of the
estimated age-specific mortality rates. Besides, there is no
information on lifestyle habits or co-morbidities (apart from
diabetes complications) reported to the Register of diabetes.
Thus, this approach can be used to objectively evaluate the
diabetic patients' health in total and to follow the changes in the
period of time, but not claim on deep causal explanations.
5. Conclusions
In Latvia the mortality of patients with diabetes exceeds
mortality in the general population by nearly 1.5 times.
Mortality rates are higher for men and older patients,
however, compared to mortality in the general population,
especially for women, and for younger patients, diabetes
increases the risk of death.
m e d i c i n a 5 0 ( 2 0 1 4 ) 1 3 0 – 1 3 6136During the period of 2000–2012 the mortality of patients with
diabetes has decreased and there is a tendency that the
mortality indicators of patients with diabetes and the mortality
indicators in the general population are becoming closer.
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